高危型HPV基因型检测在新疆宫颈癌筛查中的临床应用价值

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (754 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要目的评价高危型HPV基因型检测在宫颈癌筛查中的可行性及应用价值。方法 2014年9月—2015年8月于新疆地区行宫颈癌筛查女性564例,应用第二代反向点杂交捕获法(HC2)和液基薄层细胞检测技术(TCT)进行HPV基因型定性检测及细胞分类学诊断,对活检标本进行病理定性诊断后,采用实时荧光定量PCR方法(COBAS HPV)对剩余宫颈剩余脱落细胞进行高危型HPV(HR-HPV)基因型检测。结果高危型HPV基因型检测在诊断CIN2⁺病变时优于HC2、TCT检测,不同液基细胞学分级及组织病理分级中HR-HPV感染率不同,随细胞学及病理学诊断级别升高,HR-HPV感染率上升,HPV-16型感染率上升。各级别宫颈病变以HPV-16及合并HPV-16型感染为主,HPV-16型在维吾尔族和汉族妇女分布无差异。高危型HPV基因型检测对ASCUS分流优于HC2。结论高危型HPV感染是宫颈癌前病变和宫颈癌的主要致病因素;宫颈各级别病变中以HPV-16型及合并HPV-16型感染为主;随细胞学及病理学诊断级别升高,HR-HPV感染率上升;HR-HPV基因型检测优于HC2、TCT检测,在新疆地区宫颈癌筛查中具有较高的临床应用价值。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	马春华
	吐尔逊阿衣·买买提明
	王琳
	朱开春
	玛依努尔·尼牙孜

关键词 ：人乳头状瘤病毒, 宫颈癌, 高危型HPV基因型检测

Abstract：Objective To evaluate the feasibility and application of high-risk HPV genotyping in cervical cancer screening.Methods High-risk genotyping was carried out for cervical cell samples in 564 female patients who were underwent cervical cancer screening as well as HC2 and TCT test with pathological results in Xinjiang Uygur Autonomous Region between September 2014 and August 2015.Results For the diagnosis of CIN2⁺, high-risk HPV genotyping was better than HC2 and TCT. The difference was statistically significant (P<0.05). HR-HPV infection rate varied by TCT classification and tissue pathology grading (P<0.05). With increase in the grade of cytology and pathological diagnosis, HR-HPV infection rate (P<0.05) and HPV16 infection rate (P<0.05) were increased. All levels of cervical lesions were mainly seen in HPV16 or multiple infections including HPV16. The distribution of HPV16 in Uyghur and Han women was not statistically different (P>0.05). High-risk HPV genotyping to ASCUS bypass was superior to HC2.Conclusion High-risk HPV infection was a main pathogenic factor for precancerous change and cervical cancer. All levels of cervical lesions were associated with HPV16 or multiple infections including HPV16. HR-HPV infection rate increased with cytological and pathological diagnosis grade. High-risk HPV genotyping has clinical value in the screening of cervical cancer in Xinjiang region, and this technique is superior to HC2 and TCT.

Key words： Human Papillamavirus Cervical Cancer High-risk HPV type testing

收稿日期: 2016-01-04

基金资助:国家自然科学基金资助项目(81150317)

通讯作者: 玛依努尔·尼牙孜(mynr68@126.com)

引用本文:

马春华, 吐尔逊阿衣·买买提明, 王琳, 朱开春, 玛依努尔·尼牙孜. 高危型HPV基因型检测在新疆宫颈癌筛查中的临床应用价值[J]. 中国生育健康杂志, 2016, 27(5): 432-437.
MA Chunhua, Tuerxunayi·Maimaitiming, WANG Lin, ZHU Kaichun, Mayinue·Niyazi. Clinical value of high-risk HPV genotyping in cervical cancer screening in Xinjiang. Chinese Journal of Reproductive Health, 2016, 27(5): 432-437.

链接本文:

http://cjrh.bjmu.edu.cn/CN/ 或 http://cjrh.bjmu.edu.cn/CN/Y2016/V27/I5/432

1 Ferlay F,Autier P,Boniol M,et al.Estimates of the cancer incidence and mortality in Europe in 2006.Annals Oncol,2007,18:581-592.
2 Walboomers JMM,Jacobs MV,ManosmM,et al.Human Papillomavirus is a necessary cause of invasive cervical cancerworldwide.J Pathol,1999,189:12-19.
3 王春晓,佟林林,孙淑娥.宫颈癌流行病学调查和筛查研究进展.齐齐哈尔医学院学报,2007,28:826-830.
4 姜淑清,土送爱,周俊兰,等.新疆策勒县妇女病现状调查与分析.中国妇幼保健,2006,21:524-526.
5 古扎丽努尔·阿不力孜,程静新,米克热木,等.新疆维吾尔族妇女宫颈癌的HPV谱研究.肿瘤,2007,5:379-382.
6 De Sanjose S,Quint WG,Alemany L,et al.Human Papillomavirus genotype attribution in invasive cervical cancer:a retrospective cross-sectional worldwide study.Lancet Oncol,2010,11:1048-1056.
7 Patel A,Galaal K,Burnley C,et al.Cervical cancer incidence in young women:a historical and geographic controlled UK regional PoPulation study.Br J Cancer,2012,106:1753.
8 Forman D,de Martel C,Lacey CJ,et al.Global burden of human Papillomavirus and related diseases.Vaccine,2012,30:12.
9 Mount SL,PaPillo JL.Astudy of 10296 Preiatric and adolescent Papanicolaousmear diagnoses in northerm New Endland.Pediatrics,1999,103:539-545.
10 廖秦平,赵健,陈锐.HPV感染的处理原则及HPV检测与随访.实用妇产科杂志,2010,26:172-174.
11 陈汶,于露露,王红,等.COBAS 4800高危型人乳头瘤病毒检测技术在子宫颈癌前病变筛查和细胞学转诊中的应用.中华肿瘤杂志,2012,34:543-548.
12 李文婷,王莹,赵峰.新疆维吾尔族妇女宫颈癌中HVP16/18的表达及临床意义.新疆医科大学学报,2014,37:685-691.
13 张媛媛,古扎丽努尔·阿不力孜.人乳头状瘤病毒检测方法研究进展.新疆医科大学学报,2015,38:417-419.
14 马庆,张瑾.Cobas4800HPV检测对宫颈癌筛查的运用分析.中国性科学,2014,23:25-27.
15 CiaPPoni A,Bardach A,Glujovsky D,et al.Type-specific HPV Prevalence in cervical cancer and high-grade lesions in Latin America and the Caribbean:systematic review and meta-analysis.PLoS One,2011,6:e25493.
16 亚力坤·穆罕默德.维吾尔族及汉族妇女高危型HPV检测、L1蛋白表达与病毒整合的比较研究.乌鲁木齐:新疆医科大学,2013.
17 Arbyn M,Roelens J,Cuschieri K,et al.The APTIMA HPV assay versus the hybrid caPture 2 test in triage of women with ASC-US or LSIL cervical cytology:A metaanalysis of the diagnostic accuracy.Int J Cancer,2013,132:101-108.
18 Katki HA,Schiffman M,Castle PE,et al.Five-year risk of CINⅢ⁺ and cervical cancer for women with HPV testing of ASC-US PaP results.J Lower Genital Tract Dis,2013,17:S36-S42.
19 Lee SJ,Kim WY,Shim SH,et al.Semi-quantitative HPV viral load in Patients with ASC-US cytology:viral load correlates strongly with the Presence of CIN but only weakly with its severity.CytoPathol,2015,26:19-25.

(